Literature DB >> 20040817

Vincristine-induced acute life-threatening hyponatremia resulting in seizure and coma.

Mahesh Nagappa1, Ravindra R Bhat, K Sudeep, Sandeep Kumar Mishra, A S Badhe, B Hemavathi.   

Abstract

We report a case of a four-year-old boy with stage 1 Wilms tumour, who developed Vincristine-induced acute life- threatening hyponatremia, which presented as generalized tonic clonic seizures and coma. He was intubated and mechanically ventilated. There were no localizing neurological signs. CSF study showed no cells and CSF proteins were 20 mg%. Electrocardiography, chest X-ray, echocardiography, CT scan and liver function tests were normal. Evaluation of electrolytes and arterial blood gas showed serum sodium of 113 mEq/L with mild metabolic acidosis. Serum osmolality was 260 mOsm/L (normal value 285-295 mOsm/L) and urine osmolality was 625 mOsm/L (normal range 300-900 mOsm/L), urine sodium 280 mEq/d (normal range 100-260 mEq/d), serum potassium, blood urea, blood sugars were normal. Serial blood cultures showed no bacterial growth. Patient was treated with fluid restriction, hypertonic saline (3%) and other supportive care. Patient improved clinically over three days and was extubated on the third day and shifted to the ward on the fifth day.

Entities:  

Year:  2009        PMID: 20040817      PMCID: PMC2823101          DOI: 10.4103/0972-5229.58545

Source DB:  PubMed          Journal:  Indian J Crit Care Med        ISSN: 0972-5229


  7 in total

1.  A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone.

Authors:  W B SCHWARTZ; W BENNETT; S CURELOP; F C BARTTER
Journal:  Am J Med       Date:  1957-10       Impact factor: 4.965

2.  [Severe hemolysis and SIADH-like symptoms induced by vincristine in an ALL patient with liver cirrhosis].

Authors:  Y Nishihori; N Yamauchi; K Kuribayashi; Y Sato; K Morii; Y Hirayama; S Sakamaki; H Honma; N Suzuki; T Kudo; Y Niitsu
Journal:  Rinsho Ketsueki       Date:  2000-11

3.  Hyponatremia and vincristine therapy. Syndrome possibly resulting from inappropriate antidiuretic hormone secretion.

Authors:  R N Fine; R R Clarke; N A Shore
Journal:  Am J Dis Child       Date:  1966-09

4.  Experience with vincristine--associated neurotoxicity.

Authors:  N A Othieno-Abinya; L O Nyabola
Journal:  East Afr Med J       Date:  2001-07

5.  Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of Vincristine: an over-representation of Asians?

Authors:  Isaac W Hammond; Jeffrey A Ferguson; Kenneth Kwong; Edmundo Muniz; Frank Delisle
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002 Apr-May       Impact factor: 2.890

6.  Syndrome of inappropriate antidiuretic hormone secretion in malignancy: review and implications for nursing management.

Authors:  Lori A Langfeldt; Mary E Cooley
Journal:  Clin J Oncol Nurs       Date:  2003 Jul-Aug       Impact factor: 1.027

7.  Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of vincristine.

Authors:  M J Stuart; C Cuaso; M Miller; F A Oski
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

  7 in total
  2 in total

1.  Hyponatremia During Induction Therapy in Distinct Pediatric Oncological Cohorts: A Retrospective Study.

Authors:  Christina Salvador; Robert Salvador; Peter Willeit; Christine Kuntner; Alexandra Haid; Thomas Müller; Gabriele Kropshofer; Roman Crazzolara
Journal:  Front Oncol       Date:  2021-10-29       Impact factor: 6.244

2.  Characteristics and Outcome of Children with Wilms Tumor Requiring Intensive Care Admission in First Line Therapy.

Authors:  Anouk Steur; Paulien A M A Raymakers-Janssen; Martin C J Kneyber; Sandra Dijkstra; Job B M van Woensel; Dick A van Waardenburg; Cornelis P van de Ven; Alida F W van der Steeg; Marc Wijnen; Marc R Lilien; Ronald R de Krijger; Harm van Tinteren; Annemieke S Littooij; Geert O Janssens; Annemarie M L Peek; Godelieve A M Tytgat; Annelies M Mavinkurve-Groothuis; Martine van Grotel; Marry M van den Heuvel-Eibrink; Roelie M Wösten-van Asperen
Journal:  Cancers (Basel)       Date:  2022-02-14       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.